Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy. - Wikidata - wikimedia - TriplyDB

Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

http://www.wikidata.org/entity/Q36820215

about

Scaffold Proteins Regulating Extracellular Regulated Kinase Function in Cardiac Hypertrophy and Disease Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives Diet and sex modify exercise and cardiac adaptation in the mouse Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes.G protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway.Na+/H+ exchanger isoform 1 induced cardiomyocyte hypertrophy involves activation of p90 ribosomal s6 kinase.Non-sirtuin histone deacetylases in the control of cardiac aging The Heparan Sulfate Proteoglycan Glypican-6 Is Upregulated in the Failing Heart, and Regulates Cardiomyocyte Growth through ERK1/2 Signaling.Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation Phosphorylation or Mutation of the ERK2 Activation Loop Alters Oligonucleotide Binding.Sodium Ferulate Protects against Angiotensin II-Induced Cardiac Hypertrophy in Mice by Regulating the MAPK/ERK and JNK Pathways.The many lives of CTIP2: from AIDS to cancer and cardiac hypertrophy.Heart failure-specific changes in protein kinase signalling.Analyzing ERK 1/2 signalling and targets.From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure Regulatory roles of conserved phosphorylation sites in the activation T-loop of the MAP kinase ERK1 Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.A systemic Pasteurella multocida toxin aggravates cardiac hypertrophy and fibrosis in mice.Attenuating effects of dihydromyricetin on angiotensin II-induced rat cardiomyocyte hypertrophy related to antioxidative activity in a NO-dependent manner.Prolonged swimming promotes cellular oxidative stress and p66Shc phosphorylation, but does not induce oxidative stress in mitochondria in the rat heart.Cardiac RKIP induces a beneficial β-adrenoceptor-dependent positive inotropy.Isolation and Characterization of Intrinsically Active (MEK-Independent) Mutants of Mpk1/Erk.Endothelium Independent Effect of Pelargonidin on Vasoconstriction in Rat Aorta.Myocardial CKIP-1 Overexpression Protects from Simulated Microgravity-Induced Cardiac Remodeling.Hypothermia Inhibits Endothelium-Independent Vascular Contractility via Rho-kinase Inhibition.The A2B adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1

P2860

Q26765993-D65D10E7-0941-42DC-B97D-6A8C3EB66EFC Q26800200-C8BB648E-5BAD-4E58-B4A5-967705ECCA64 Q28075539-D67D9F1F-3300-4933-AC07-0E0291482887 Q28552721-ECA8E676-FA28-4321-A2A5-E51ABBCEB7D6 Q34289211-0AB01537-D4A8-4388-A484-2A96416EAFF5 Q35115827-4A5C1564-79DF-481F-A59B-9951E3C288C6 Q35128221-B85B0E6B-D5F4-4788-A8F0-BF4209312308 Q35171028-E4560A88-98AE-4E6E-AB51-16B9EE18E2FB Q35591765-9659A1DE-41E6-4B87-BF43-CC9ED3F3127B Q35695849-8D4378D4-56E2-4141-A79B-291272D6BA9B Q36170775-D77F1C1B-ED3F-412C-92C4-5442844E501D Q36685109-BE371F50-C4F8-46EF-B377-2E41CD33DEC3 Q37515818-4CCDD183-35E5-4F0E-BC6F-508AF860C7AA Q37601816-D6366F0C-B702-4D77-BE2D-C39A4558FEAD Q38152295-6819DE7D-01A2-47DA-8B7F-7F7D55D3091F Q38186583-301B5581-1FCE-497E-877D-C3340FD76BB6 Q38764430-E28499AA-7C8E-424D-B02E-96134483AC9C Q38780801-C856AC7C-64E3-42C5-A478-B3E82080B5F7 Q38798535-17FA48FA-14F0-4054-AA0D-03F4C3479A23 Q39263982-81E73BF7-4ACC-4C94-A44F-C4B0CA96D233 Q41249294-4257A961-6221-4FD4-982D-AB9A3333EFFA Q46803440-6280947F-35D4-4845-84B5-50E1C3BBC745 Q46829144-73B98A79-5C40-419B-8FC7-93941A9FFFB6 Q48118068-3F125D15-7261-435F-9885-F2FA5AB7FBF5 Q48910824-D11071CF-9BEA-4CC1-B373-F7C2C145183B Q49488230-C51B8EE7-B913-444E-B6F2-2BB5A9539F8E Q50106217-201941CB-DB20-4487-9841-9A25B1E3D1B0 Q53121132-585610FC-1224-46E2-B8B6-6EFC874C8F0F Q58696098-4173A2F7-AAC7-4EE1-A024-103FB89418E8

P2860

Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

http://www.wikidata.org/entity/Q36820215

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Interference with ERK(Thr188) ...... iological cardiac hypertrophy.

@en

type

label

Interference with ERK(Thr188) ...... iological cardiac hypertrophy.

@en

prefLabel

Interference with ERK(Thr188) ...... iological cardiac hypertrophy.

@en

P1433

Q36820215-D5DAB6EC-9FE9-49F2-A6FF-17F79C98CFF3

P1476

Q36820215-01E00B78-53DD-409F-B06D-91483CD13FF5

P2093

Q36820215-08F4B25D-23DD-469F-BC8E-CD45C80628AA

Q36820215-135D1409-07A7-4BD2-8D8A-A61B4ECCD8A2

Q36820215-29CDE39A-95C6-42AD-BA39-69C452BD0656

Q36820215-38146100-CE9A-4392-8803-2EF0B7BC39E1

Q36820215-8C79F1C4-E82E-4383-B23E-058C128B3CE9

Q36820215-AEA0F295-A00A-42BF-8165-19FEED77EAEF

Q36820215-B517243C-82B0-4D2D-8970-7E442275C133

Q36820215-C9F2D0A3-FDB4-4B9C-8A30-75ED3E22EBF2

Q36820215-EEDD2075-CDD6-4827-B588-3AD5C9DEAF75

P2860

Q36820215-041EEDF9-5EAF-459A-811E-AEA3B0618341

Q36820215-059474FC-A99A-4F49-BB8D-DC87A7070FB6

Q36820215-0D790954-6A35-47B0-8F31-B575AB4CD1E1

Q36820215-1CE57215-E835-483C-BD3A-23CC464B4690

Q36820215-2592B071-BD2B-4E73-8BDC-840462735B38

Q36820215-27466944-A79C-464B-935F-56AF205C2FA2

Q36820215-2C176513-3574-4A8D-A88B-9FED592A5098

Q36820215-3026F940-2A6D-4F63-8D36-BC1C3E2FB8EF

Q36820215-312B0DB6-DC92-4B34-9A53-4215EF63D897

Q36820215-33144842-1C47-46FD-BC1B-86692E9D9DD2

P304

Q36820215-8DAE5755-E820-47FD-8AA8-F86B06E70B96

P31

Q36820215-EB78475D-CEBC-4F75-AAA3-1DE09555BAAC

P356

Q36820215-E7E68D21-EFD7-4D16-AE7D-C6553CC46E8F

P407

Q36820215-68E7353E-FA12-496A-9F97-B86C73B3BADB

P433

Q36820215-64A47E45-E648-4BFD-A3A0-33CD2338F7DC

P478

Q36820215-DA0B1CB9-5013-4E78-82EA-667985A4DF93

P577

Q36820215-9014285D-3260-4B1E-9FEF-262DB97E9C85

P5875

Q36820215-19785E10-4BB4-4B87-B921-5EFEDDED2677

P698

Q36820215-A35A51BD-FC49-422E-8CB9-D1EEE5F48C21

P921

Q36820215-91BC2799-0522-4C0B-8BED-F1A714BA0F72

P932

Q36820215-0AA8850A-C868-45AF-8444-F73ED9879A8E

P356

PNAS.1221999110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Interference with ERK(Thr188) ...... iological cardiac hypertrophy.

@en

P2093

Armin Gorski

http://www.w3.org/2001/XMLSchema#string

Catharina Ruppert

http://www.w3.org/2001/XMLSchema#string

Frank Weidemann

http://www.w3.org/2001/XMLSchema#string

Katharina Deiss

http://www.w3.org/2001/XMLSchema#string

Kristina Lorenz

http://www.w3.org/2001/XMLSchema#string

Marie Vidal

http://www.w3.org/2001/XMLSchema#string

Martin J Lohse

http://www.w3.org/2001/XMLSchema#string

Mehmet Oezkur

http://www.w3.org/2001/XMLSchema#string

Sebastian Herrmann

http://www.w3.org/2001/XMLSchema#string

P2860

CIB1 is a regulator of pathological cardiac hypertrophy

Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.

The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death

Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis

Cardiac myocyte gene expression profiling during H2O2-induced apoptosis

Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes

Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2

Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

P304

7440-7445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1221999110

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236186463

http://www.w3.org/2001/XMLSchema#string

P698

23589880

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

3645583

http://www.w3.org/2001/XMLSchema#string